

**34th EDRN Steering Committee Meeting and
6th Annual US Japan Workshop on Cancer Biomarkers in
Collaboration with NCI Early Detection Research Network
March 18-20, 2019
Hilton Garden Inn, Downtown
Nashville, Tennessee**

**Lung and Upper Aerodigestive Cancers
Collaborative Group Meeting**

**Wednesday March 20, 2019
8:00 a.m. – 12:00 p.m.**

Room: Skyline Junior Ballroom

Chair:

Pierre Massion, M.D., Vanderbilt-Ingram Cancer Center, Vanderbilt University
Medical Center

Co-Chair:

James Herman, M.D., University of Pittsburgh Cancer Institute

NCI Program Directors:

Lynn Sorbara, Ph.D., and Karl Krueger, Ph.D., National Cancer Institute

Agenda

7:00 a.m. – 8:00 a.m. Sign-In and Continental Breakfast

8:00 a.m. – 8:10 a.m. Welcome and Introduction

**Each Site should include/respond to the following questions as a “self-
evaluation” for their specific group:**

**Are there any biomarkers in lung and related organs that are ready for
validation? Rank them in terms of their readiness (Phase I, Phase II or Phase
III) for validation. Then answer the following:**

- 1. What is the intended use, e.g., screening; clinical decision of biopsy; repeat biopsy, etc.**
- 2. What is the type of marker or biomarker panel?**
- 3. What is the type(s) of specimens (tissue, blood and or urine)?**
- 4. How does the new biomarker or the new panel of biomarkers add to the current knowledge baseline?**
- 5. What are the parameters of sensitivity, specificity, PPV, NPV, AUC and how does this compare to the current standard of care?**

**34th EDRN Steering Committee Meeting and
6th Annual US Japan Workshop on Cancer Biomarkers in
Collaboration with NCI Early Detection Research Network
March 18-20, 2019
Hilton Garden Inn, Downtown
Nashville, Tennessee**

**Lung and Upper Aerodigestive Cancers
Collaborative Group Meeting**

- 8:10 a.m. – 8:35 a.m. A Combined Imaging, Blood, and Clinical Biomarker Strategy for Lung Cancer Risk Reclassification in Patients with Indeterminate Pulmonary Nodules
Michael Kammer, Ph.D. and Pierre Massion, M.D.,
Vanderbilt-Ingram Cancer Center, Vanderbilt
University Medical Center
- 8:35 a.m. – 9:00 a.m. The Status of Novel Diagnostic and Prognostic Assays for Mesothelioma and Lung Cancer
Harvey Pass, M.D., New York University School of
Medicine, NYU Langone Medical Center
- 9:00 a.m. – 9:25 a.m. Updates from the BU/UCLA Lung Cancer Biomarker Discovery Lab
Marc Lenburg, Ph.D., Boston University
- 9:25 a.m. – 9:50 a.m. Optimizing DNA Methylation Methods for Clinical Use in Lung Cancer Detection
○ Tom Pisanic, Ph.D., Johns Hopkins University
○ James Herman, M.D., University of Pittsburgh
Cancer Institute
- 9:50 a.m. – 10:00 a.m. Break**
- 10:00 a.m. – 10:20 a.m. Peripheral Immunity, Gene Expression and Lung Cancer Diagnosis
Rehman A. Qureshi, Ph.D., and Louise Showe, Ph.D.,
The Wistar Institute

**34th EDRN Steering Committee Meeting and
6th Annual US Japan Workshop on Cancer Biomarkers in
Collaboration with NCI Early Detection Research Network
March 18-20, 2019
Hilton Garden Inn, Downtown
Nashville, Tennessee**

**Lung and Upper Aerodigestive Cancers
Collaborative Group Meeting**

- 10:20 a.m. – 10:40 a.m. Moffitt Imaging Biomarker Validation Center
Matthew Schabath, Ph.D., H. Lee Moffitt Cancer
Center and Research Institute, Inc.
- 10:40 a.m. – 11:05 a.m. miRNA as Biomarkers for Early Detection of Non-
Small Cell Lung Cancer in Sputum
Sanford Stass, M.D., and Feng Jiang, Ph.D.,
University of Maryland School of Medicine
- 11:05 a.m. – 11:30 a.m. LPT2 (Nodule) Update
 - Pierre Massion, M.D., Vanderbilt-Ingram Cancer
Center, Vanderbilt University Medical Center
 - Tracey Marsh, Ph.D., Fred Hutchinson Cancer
Research Center
- 11:30 a.m. – 12:00 p.m. Wrap-up and General Project Discussions